Physician profile
Kanwardeep Singh
NPI 1477713378
$548.30
in general payments reported to CMS, 2019-2025
12 companies · $187 in 2025
The $187 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $156 · 2022: $27.40 · 2023: $45.67 · 2024: $133 · 2025: $187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $365.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $364.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $125.00 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $120.97 | 2024-2025 | Lifevest |
| Ucb, INC. | $75.10 | 2024-2025 | Briviact |
| Chiesi USA, INC. | $59.98 | 2024-2025 | Cleviprex |
| Novartis Pharmaceuticals Corporation | $30.02 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $29.95 | 2023 | Zerbaxa, Dificid, Recarbrio |
| Pfizer INC. | $25.60 | 2025 | |
| Paratek Pharmaceuticals, INC. | $22.54 | 2025 | Nuzyra |
| E.R. Squibb & Sons, L.L.C. | $15.84 | 2021 | |
| Mylan Specialty L.P. | $15.72 | 2023 | Yupelri |
| Astrazeneca Pharmaceuticals Lp | $14.94 | 2025 | |
| Philips North America LLC | $12.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kanwardeep Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.